These 2 Biotech Stocks Are Set to Soar
Investing in biotech companies, especially relatively small ones, can be a double-edged sword. Their shares often soar on strong clinical trial or regulatory news, but they can lose much of their value overnight if a study's results don't go their way. That makes many biotech stocks somewhat risky investments, but some could deliver excellent results for those who can stomach the risk.
Two biotech companies whose shares could gain significant traction in the months and years ahead are Viking Therapeutics (NASDAQ: VKTX) and Sarepta Therapeutics (NASDAQ: SRPT).
Viking Therapeutics is a clinical-stage biotech whose stock rose significantly this year. The drugmaker owes that run-up to its leading candidate, VK2735, a potential GLP-1 weight loss therapy that produced strong results in a phase 2 study. At least two scenarios could lead to Viking's shares soaring even more in the coming months and years.
Source Fool.com
Viking Therapeutics Inc Aktie
Einige Buy-Einschätzungen bei Viking Therapeutics Inc überwiegen die Sell-Einschätzungen leicht.
Ein Kursziel von 110 € für Viking Therapeutics Inc würde eine Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 55.78 € bedeuten.
